Milan

• Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma Ended recruitment
  2024-514122-23-00 4 2021-10-07 Marginal Zone Lymphomas refractory to or in first or greater relapse a
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended recruitment
  2023-508838-33-00 5 2021-10-06 Chronic Myeloid Leukemia
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro … Ended recruitment
  2024-510812-64-00 5 2021-09-30 Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin recep
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun … Ended recruitment
  2023-507494-18-00 5 2021-09-24 Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosin
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung … Ended recruitment
  2024-513770-22-00 4 2021-09-22 Malignant Solid Tumors - Non Small Cell Lung Cancer
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec … Ended recruitment
  2024-512038-13-00 5 2021-09-16 Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
• A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended recruitment
  2024-513397-21-00 4 2021-09-16 Relapsed Multiple Myeloma
• Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended recruitment
  2024-514461-19-00 9 2021-09-09 Solid Tumors
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)
• A Phase 2 Study of Avutometinib (VS-6766) Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAM … Ended recruitment
  2024-516986-35-00 4 2021-09-06 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended recruitment
  2023-504734-21-00 5 2021-08-30 Psoriatic arthritis (PsA)
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu … Ended recruitment
  2023-508194-89-00 4 2021-08-30 Persistent or Recurrent Rare Epithelial Ovarian Tumors
• A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended recruitment
  2023-507687-38-00 9 2021-08-23 Participants with extensive-stage small cell lung cancer
• Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A … Ended recruitment
  2023-507963-20-00 5 2021-08-19 Metastatic Gastric Adenocarcinoma
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended recruitment
  2022-502856-29-00 7 2021-07-27 Advanced Solid Tumors
• Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease. Ended recruitment
  2024-512978-99-00 4 2021-07-19 Chronic graft versus host disease (cGVHD)
• Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen … Ended recruitment
  2023-505637-27-00 5 2021-07-12 Spinal Muscular Atrophy
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended recruitment
  2023-507697-40-00 5 2021-07-05 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) Ended recruitment
  2023-505089-27-00 5 2021-07-01 Atypical Hemolytic Uremic Syndrome (aHUS)

Showing 1,609–1,632 of 2,361 trials